araag2/HINT huggingface dataset:
Clinical trial NCT02289963 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: placebo (for alirocumab), alirocumab, lipid-modifying therapy (lmt)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

        Participants with hypercholesterolemia and established coronary heart disease (CHD) or CHD
        risk equivalents who are not adequately controlled with a maximally tolerated daily dose of
        statin with or without other LMT, both at stable dose for at least 4 weeks prior to
        screening visit (Week -3).

        Exclusion criteria:

          -  Aged <18 years or legal age of adulthood, whichever was greater.

          -  Participants without established CHD or CHD risk equivalent.

          -  LDL-C <70 mg/dL (<1.81 mmol/L) in participants with a history of documented
             cardiovascular disease.

          -  LDL-C <100 mg/dL (<2.59 mmol/L) in participants without a history of documented
             cardiovascular disease.

          -  Not on a stable dose of LMT (including statin) for at least 4 weeks prior to the
             screening visit (Week -3) or between screening to randomization visits.

          -  Currently taking a statin other than atorvastatin, rosuvastatin or simvastatin.

          -  Atorvastatin, rosuvastatin or simvastatin was not taken daily or not taken at a
             registered dose.

          -  Daily doses above atorvastatin 80 mg, rosuvastatin 20 mg or simvastatin 40 mg.

          -  Fasting serum triglycerides >400 mg/dL (>4.52 mmol/L) at the screening period.

        The above information is not intended to contain all considerations relevant to a
        participants's potential participation in a clinical trial.
Clinical trial NCT02291679 (phase 3, status: completed)
Conditions: chronic idiopathic constipation
ICD codes: K59.04
Drugs: linaclotide, matching placebo
SMILES: [H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has completed a colonoscopy if one is needed according to the American
             Gastroenterological Association (AGA) criteria, with no clinically significant
             findings

          -  Patient has no clinically significant findings on a physical examination and clinical
             laboratory tests

          -  Patient meets protocol criteria for CIC: reports < 3 bowel movements (BMs) per week
             and reports one or more of the following during ≥ 25% of BMs: straining, lumpy or hard
             stools, sensation of incomplete evacuation during the 3 months before the diagnosis
             with the onset at least 6 months before the diagnosis

          -  Patient is compliant with daily interactive voice response system (IVRS) calls

          -  Patient reports an average of < 3 complete spontaneous BMs (CSBMs) and ≤ 6 SBMs per
             week by the IVRS over the 14 calendar days before the Randomization Visit and the
             calendar day of Randomization.

        Exclusion Criteria:

          -  Patient has history of loose or watery stools

          -  Patient has symptoms of or been diagnosed with irritable bowel syndrome (IBS)

          -  Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease
             or condition that can affect GI motility

          -  Patient has any protocol-excluded or clinically significant medical or surgical
             history that could confound the study assessments

          -  Patient has Bristol Stool Form Scale score of 7 during Pretreatment period.
Clinical trial NCT02291861 (phase 3, status: completed)
Conditions: tardive dyskinesia
ICD codes: K22.4, G24.01
Drugs: sd-809, placebo
SMILES: [2H]C([2H])([2H])OC1=CC2=C(C=C1OC([2H])([2H])[2H])[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of using a dopamine receptor antagonist for at least 3 months

          -  Clinical diagnosis of tardive dyskinesia and has had symptoms for at least 3 months
             prior to screening

          -  Subjects with underlying psychiatric diagnosis are stable and have no change in
             psychoactive medications

          -  Have a mental health provider and does not anticipate any changes to treatment regimen
             in the next 3 months

          -  History of being compliant with prescribed medications

          -  Able to swallow study drug whole

          -  Be in good general health and is expected to attend all study visits and complete
             study assessments

          -  Female subjects must not be pregnant and must agree to an acceptable method of
             contraception throughout the study

        Exclusion Criteria:

          -  Currently receiving medication for the treatment of tardive dyskinesia

          -  Have a neurological condition other than tardive dyskinesia that may interfere with
             assessing the severity of dyskinesias

          -  Have a serious untreated or undertreated psychiatric illness

          -  Have recent history or presence of violent behavior

          -  Have unstable or serious medical illness

          -  Have evidence of hepatic impairment

          -  Have evidence of renal impairment

          -  Have known allergy to any component of SD-809 or tetrabenazine

          -  Has participated in an investigational drug or device trial and received study drug or
             device within 30 days

          -  Have acknowledged use of illicit drugs

          -  Have a history of alcohol or substance abuse in the previous 12 months
Clinical trial NCT02292446 (phase 3, status: completed)
Conditions: polycythemia vera
ICD codes: D45
Drugs: ruxolitinib
SMILES: N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
Eligibility criteria:

        Inclusion Criteria:

        •Confirmed diagnosis of PV according to the 2008 World Health Organization criteria,
        palpable spleen, Resistant to or intolerant of hydroxyurea, ECOG performance status of 0, 1
        or 2; did not have access to a comparable or satisfactory alternative treatment

        Exclusion Criteria:

        •Inadequate liver or renal function, Significant bacterial, fungal, parasitic, or viral
        infection requiring treatment, Active malignancy within the past 5 years, except treated
        cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or squamous cell
        carcinoma of the skin, with no evidence for recurrence in the past 3 years., Women who were
        pregnant or nursing.
Clinical trial NCT02292667 (phase 3, status: unknown status)
Conditions: aortic aneurysm, abdominal, pain, anesthesia, local
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, O89.3, O29.3X1, O29.3X2, O29.3X3, O29.3X9, O74.4
Drugs: pca with chlorhydrate of morphine, acetaminophen
SMILES: OC(=O)[C@@H]1CCC(=O)N1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  ASA (American Society of Anesthesiologists) physical status 1, 2 or 3

          -  Elective surgery for open repair of an aortic abdominal aneurysm performed in the
             Vascular Surgery Unit of the University Hospital of Besancon

          -  Informed consent given

          -  Health medical insurance affiliation

        Exclusion Criteria:

          -  Poor adherence to protocol attended

          -  Incapacity to consent

          -  Pregnancy and/or breast feeding

          -  Endovascular repair of aortic abdominal aneurysm

          -  Emergent surgery of a rupture or a fissuration of aortic abdominal aneurysm

          -  Chronic medical treatment by clopidogrel if clopidogrel not stopped 5 days before
             surgery at least

          -  Chronic medical treatment by prasugrel if prasugrel not stopped 7 days before surgery
             at least

          -  Chronic medical treatment by ticlopidine, inhibitors of phosphodiesterase , inhibitors
             of glycoprotein IIb/IIIa, adenosine triphosphate analogs or thrombin receptor
             antagonists

          -  Congenital or acquired bleeding disorder

          -  Incapacity to use patient-controlled analgesia device

          -  Chronic opioid abuse or dependence

          -  Chronic renal failure defined as a clearance < 30 ml/min

          -  Severe hepatic failure

          -  Other contraindications to ropivacaïne (allergy, medical history of porphyria,
             hypovolemia)

          -  Contraindications to acetaminophen

          -  Contraindications to morphine
Clinical trial NCT02293902 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: sarilumab sar153191 (regn88), methotrexate, folic acid
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1
Eligibility criteria:

        Inclusion criteria:

          -  Diagnosis of RA, according to the American College of Rheumatology/The European League
             Against Rheumatism (ACR/EULAR) 2010 Rheumatoid Arthritis Classification Criteria with
             >=3 months disease duration.

          -  Moderately to severely active RA defined as:

          -  At least 8 of 68 tender joints and 6 of 66 swollen joints at screening visit.

          -  High sensitivity C-Reactive Protein (hs-CRP) >=6mg/L at screening visit.

        Exclusion criteria:

          -  Participants <20 or >75 years of age.

          -  Treatment with any Disease-modifying antirheumatic drug (DMARD) other than MTX or
             biologic agent without the appropriate off-drug period prior to screening.

          -  Prior treatment with anti-interleukin-6 (anti-IL-6) or anti-interleukin-6 receptor
             (IL-6R) antagonist therapies, including but not limited to tocilizumab or sarilumab.

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT02294058 (phase 3, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: ozanimod, interferon beta-1a, placebo to ozanimod, placebo to interferon beta-1a
SMILES: CC(C)OC1=CC=C(C=C1C#N)C1=NC(=NO1)C1=CC=CC2=C1CC[C@@H]2NCCO, [Na+].[Cl-], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria

          -  EDSS score between 0 and 5.0 at baseline

        Exclusion Criteria:

        • Primary progressive multiple sclerosis
Clinical trial NCT02294461 (phase 3, status: active, not recruiting)
Conditions: progressive metastatic prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: enzalutamide, placebo
SMILES: CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC=C(C#N)C(=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate without neuroendocrine
             differentiation or small cell features

          -  Ongoing androgen deprivation therapy with a GnRH analogue or bilateral orchiectomy

          -  Progressive disease despite androgen deprivation therapy as defined by rising PSA
             levels or progressive soft tissue or bone disease

          -  No prior treatment with cytotoxic chemotherapy

          -  Asymptomatic or mildly symptomatic from prostate cancer

        Exclusion Criteria:

          -  Severe concurrent disease, infection, or co-morbidity that, in the judgment of the
             Investigator, would make the patient inappropriate for enrollment

          -  Known or suspected brain metastasis or active leptomeningeal disease

          -  History of another malignancy within the previous 5 years other than curatively
             treated non-melanomatous skin cancer

          -  History of seizure including febrile seizure or any condition that may predispose to
             seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss
             of consciousness requiring hospitalization).
Clinical trial NCT02294474 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sar342434, humalog, insulin glargine hoe901
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion criteria:

          -  Participants with T2DM diagnosed for at least 12 months and treated with insulin
             glargine and Humalog®/Liprolog® or NovoLog®/NovoRapid® (at least 3 times daily, before
             each meal) in the 6 months prior to the screening visit.

          -  Signed written informed consent.

        Exclusion criteria:

          -  At screening visit, age under legal age of adulthood.

          -  HbA1c <6.5% or >10.0% at screening.

          -  Diabetes other than T2DM.

          -  Pregnancy and lactation.

          -  Women of childbearing potential not protected by highly effective contraceptive method
             of birth control.

          -  Use of insulin pump in the 6 months before screening visit.

          -  Use of insulin other than insulin glargine and Humalog or NovoLog/NovoRapid in the 6
             months prior to screening visit. Liprolog® is an European Union (EU) approved insulin
             lispro and is allowed in those countries where it is marketed.

          -  Use of Humalog/Liprolog or Novolog/NovoRapid less than 3 times daily, before each
             meal.

          -  Use of non-injectable peptides (eg, Glucagon-like peptide-1 (GLP-1) receptor-agonists
             or other peptides) in the 6 months prior to screening visit.

          -  Body mass index (BMI) >=40kg/m² at screening visit.

          -  Hospitalization for diabetic ketoacidosis in the last 6 months before screening visit.

          -  Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic
             retinopathy or macular edema likely to require treatment (eg, laser, surgical
             treatment, or injectable drugs) during the study period.

          -  The above information is not intended to contain all considerations relevant to a
             participant's potential participation in a clinical trial
Clinical trial NCT02298192 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/liraglutide
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Male or female equal to or above 18 years of age

          -  HbA1c (glycosylated haemoglobin) 7.0 - 10.0% [53 mmol/mol - 86 mmol/mol] (both
             inclusive), confirmed by the central laboratory

          -  Stable daily treatment with metformin (above or equal to 1500 mg or max tolerated
             dose) with or without pioglitazone (above orequal to 30 mg) for at least 90 days prior
             to screening

          -  Body Mass Index (BMI) below or equal to 40 kg/m^2

        Exclusion Criteria:

          -  Current use of any anti-diabetic drugs (except for metformin and pioglitazone) or
             anticipated change in concomitant medication, which, in the opinion of the
             investigator, could interfere with the glucose metabolism (e.g. systemic
             corticosteroids)

          -  Previous and / or current treatment with insulin (short term treatment due to
             intercurrent illness, including gestational diabetes, is allowed at the discretion of
             the investigator)

          -  Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, sulpfonylurea,
             glinides, dipeptidyl peptidase 4 (DPP-4) inhibitors or sodium-glucose co-transporter 2
             (SGLT2) inhibitors within 90 days prior to the screening visit

          -  Impaired liver function, defined as alanine aminotransferase (ALAT) above or equal to
             2.5 times upper normal range (UNR)

          -  Impaired renal function defined as serum-creatinine above or equal to 133 micromol/L
             (above or equal to 1.5 mg/dL) for males and above or equal to 125 micromol/L (above or
             equal to 1.4 mg/dL) for females, or as defined according to local contraindications
             for metformin

          -  Screening calcitonin above or equal to 50 ng/L

          -  Proliferative retinopathy or maculopathy (macular oedema) requiring acute treatment,
             according to investigator's clinical judgment

          -  Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine
             neoplasia type 2 (MEN2)

          -  History of pancreatitis (acute or chronic)
Clinical trial NCT02300558 (phase 3, status: terminated)
Conditions: long qt syndrome type 3
ICD codes: D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0
Drugs: eleclazine, eleclazine placebo
SMILES: FC(F)(F)OC1=CC=C(C=C1)C1=CC=C2OCCN(CC3=NC=CC=N3)C(=O)C2=C1, FC(F)(F)OC1=CC=C(C=C1)C1=CC=C2OCCN(CC3=NC=CC=N3)C(=O)C2=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Individuals with an established diagnosis of LQT3 (by genotype testing)

          -  Mean (of triplicate) QTc interval ≥ 480 msec (or ≥ 460 msec, for individuals who are
             currently taking ranolazine or Class I antiarrhythmic drugs such as mexiletine) at 3
             or more time points, determined by standard 12-lead ECG, at screening

        Key Exclusion Criteria:

          -  Known mutations associated with type 1 long QT syndrome (LQT1) or type 2 long QT
             syndrome (LQT2)

          -  Known or suspected history of seizures or epilepsy

          -  History of heart failure defined as New York Heart Association (NYHA) Class IV and/or
             known left ventricular ejection fraction (EF) ≤ 45%

          -  Body mass index (BMI) ≥ 40 kg/m^2 at screening

          -  Severe renal impairment at screening (defined as an estimated glomerular filtration
             rate (eGFR) < 30 mL/min/1.73m^2, using the 4 Variable Modification of Diet in Renal
             Disease (MDRD) equation, as determined by the study center)

          -  Abnormal liver function tests at screening, defined as alanine aminotransferase (ALT)
             or aspartate aminotransferase (AST) > 2 x upper limit of normal (ULN), or total
             bilirubin > 1.5 x ULN

          -  An aborted cardiac arrest (ACA), implantable cardioverter-defibrillator (ICD)
             implantation, syncopal episode, or appropriate ICD therapy within 3 months prior to
             screening

          -  Any other condition or circumstance that in the opinion of the investigator would
             preclude compliance with the study protocol

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02301156 (phase 3, status: completed)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: ublituximab, ibrutinib
SMILES: NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Previously treated Chronic Lymphocytic Leukemia (CLL) requiring treatment

          -  At least one high-risk cytogenetic feature defined by the presence of 17p deletion,
             11q deletion and/or p53 mutation

          -  Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

        Exclusion Criteria:

          -  Any major surgery, chemotherapy or immunotherapy within the last 21 days

          -  Evidence of hepatitis B virus, hepatitis C virus or known HIV infection

          -  Autologous hematologic stem cell transplant within 3 months of study entry. Prior
             Allogeneic hematologic stem cell transplant is excluded

          -  Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's
             transformation)

          -  Previous therapy with ibrutinib, or any drug that specifically inhibits Bruton's
             tyrosine kinase (BTK)
Clinical trial NCT02307682 (phase 3, status: completed)
Conditions: neovascular age-related macular degeneration, choroidal neovascularization
ICD codes: H35.3211, H35.3212, H35.3221, H35.3222, H35.3231, H35.3232, H35.3291, H44.2A1, H44.2A2, H44.2A3, H44.2A9, H35.3231, H35.3232, H35.3211
Drugs: brolucizumab ophthalmic solution, aflibercept ophthalmic solution
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Provide written informed consent

          -  Active choroidal neovascularization (CNV) lesions secondary to age-related macular
             degeneration (AMD) that affected the central subfield in the study eye at Screening;

          -  Total area of CNV comprising >50% of the total lesion area in the study eye at
             Screening;

          -  Intraretinal and/or subretinal fluid affecting the central subfield of the study eye
             at Screening;

          -  Best Corrected Visual Acuity (BCVA) between 78 and 23 letters, inclusive, in the study
             eye at Screening and Baseline using Early Treatment Diabetic Retinopathy Study (ETDRS)
             testing.

        Key Exclusion Criteria:

          -  Any active intraocular or periocular infection or active intraocular inflammation in
             either eye at Baseline;

          -  Central subfield of the study eye affected by fibrosis or geographic atrophy or total
             area of fibrosis >50% of the total lesion in the study eye at Screening;

          -  Subretinal blood affecting the foveal center point and/or >50% of the lesion of the
             study eye at Screening;

          -  Any approved or investigational treatment for neovascular age-related macular
             degeneration (nAMD) in the study eye at any time;

          -  Retinal pigment epithelial rip/tear in the study eye at Screening or Baseline or
             current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within
             4 weeks prior to Baseline;

          -  Pregnant or nursing women; women of child-bearing potential;

          -  Stroke or myocardial infarction in the 90-day period prior to Baseline.